TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.SJ Isakoff, Leif W. Ellisen, Erica L. Mayer et al.|Journal of Clinical Oncology|2011Cited by 35